Ascendis Pharma reports promising phase III data

The company has shown statistical significance for Transcon PTH as a treatment for hypoparathyroidism.
Photo: Kevin Grønnemann / MedWatch
Photo: Kevin Grønnemann / MedWatch
by christian bundgaard, translated by catherine brett

Ascendis Pharma has released the final phase III data from its clinical studies of candidate Transcon PTH as a treatment for hypoparathyroidism, which causes cramps and muscle spasms due to low levels of calcium and PTH.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading